Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
68.40
-2.30 (-3.25%)
Mar 9, 2026, 2:45 PM EDT - Market open
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
$1,026,230
Profits / Employee
-$1,979,279
Market Cap
1.91B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Iovance Biotherapeutics | 975 |
| Ascentage Pharma Group International | 605 |
| Syndax Pharmaceuticals | 298 |
| Celldex Therapeutics | 198 |
| Soleno Therapeutics | 182 |
| Stoke Therapeutics | 128 |
| Aurinia Pharmaceuticals | 128 |
NKTR News
- 7 hours ago - Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR) - Newsfile Corp
- 2 days ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 10 days ago - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets - PRNewsWire
- 12 days ago - Nektar Therapeutics to Participate in Two Investor Conferences in March - PRNewsWire
- 19 days ago - Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy - Seeking Alpha
- 20 days ago - Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis - PRNewsWire
- 23 days ago - Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 24 days ago - Can NKTR Stock Sustain Its 1,000% Rally? - Forbes